Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 209 | 48 | 158 |
| Samples | 206 | 46 | 157 |
| Peptides | 141 | 29 | 113 |
Function
GPR182 · Atypical chemokine receptor 5
Atypical chemokine receptor that regulates chemokine levels and localization through chemokine binding, independently of activating classical ligand-induced signaling pathways such as G protein activation and Ca(2+) mobilization (PubMed:33875597, PubMed:35013216, PubMed:37554323, PubMed:38026988). Instead, it mediates chemokine sequestration, transport, or internalization to control their availability (PubMed:33875597, PubMed:35013216, PubMed:37554323, PubMed:38026988). Acts as a scavenger for a broad range of chemokines from CXC, CC and XC chemokine ligand families including CXCL9, CXCL10, CXCL12, CXCL13, CXCL11, CXCL14, CCL1, CCL11, CCL19, CCL25, CCL28 and XCL1 (PubMed:33875597, PubMed:35013216, PubMed:38026988). Is the only atypical receptor for chemokines CXCL13 and CCL28 (PubMed:37554323). Has a strong constitutive association with beta-arrestins, which is essential for intracellular receptor trafficking and chemokine scavenging, and occurs independently of ligand binding (PubMed:33875597, PubMed:37554323). Cooperates with ACKR3 and ACKR4 in regulating serum levels of CXCL12 and CCL19, respectively (PubMed:37554323). Acts as an important modulator of cellular immunity (By similarity)
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000300098 | O15218 | 206 | 138 |
| ENST00000622922 | A0A0D9SEW8* | 3 | 3 |
Gene Properties
Recurrent Mutations
All 138 amino-acid changes on canonical ENST00000300098 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GPR182 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GPR182 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 12/612 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Other Solid Cancers | 2/94 2% | 18/1515 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Colorectal Carcinoma | 8/143 6% | 26/3239 1% |
| Gastric Carcinoma | 0/74 0% | 18/1809 1% |
| Melanoma | 6/210 3% | 14/1899 1% |
| Esophageal Carcinoma | 1/23 4% | 5/769 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Neuroendocrine Tumour | 5/154 3% | 0/577 0% |
| Non-Small Cell Lung Carcinoma | 9/304 3% | 1/1390 0% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
| Ovarian Carcinoma | 3/109 3% | 1/998 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Biliary Tract Carcinoma | 1/54 2% | 2/950 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Pancreatic Carcinoma | 1/89 1% | 2/1611 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 2/2534 0% |
Mutation Distribution
Where GPR182 is mutated · all tissues, split by cell line vs tissue
How many mutations in GPR182 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 209 mutations in GPR182
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|